FDA Investigator Montgomery Montgomery, Karen M
Montgomery Montgomery, Karen M has conducted inspections on 1 sites in 1 countries as of 06 Oct 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
1
Last Inspection Date:
06 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Montgomery Montgomery, Karen M:
Andrace L Deyampert,
Andrea D Swingle,
Bei Y He,
Benjamin J Smith,
Byungja E Marciante,
Charles I Ann,
Charles L Zhou,
Constantin Y Philopoulos,
Corrine M Carter,
David A Paterson,
Debara R Reese,
Debara Reese,
Denise L Burosh,
Dennis E Guilfoyle, PhD,
Dina A Tallman,
Donald C Obenhuber, PhD,
Emest F Bizjak,
Emily J Orban,
Jean Blackston Hill,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer A Kemp,
Joseph A Piechocki,
Joseph R Strelnik,
Karen M Montgomery (KMM),
L'oreal F Walker,
Larry K Austin,
Lauren Iacono Connors, PhD,
Leigh Anne Myers,
Lisa M Bellows,
Luella J Rossi,
Meisha R Sampson,
Meisha Waters,
Melina Lrodriguez Upton,
Mercy Oyugi,
Michael Shanks, MS,
Michele L Forster, PhD,
Muna Algharibeh,
Myra K Casey,
Nailing Zhang,
Neali H Lucas,
Patricia A Cochran,
Patricia H Dlugosz,
Patrick B Cummings,
Patsy J Domingo,
Qiao Y Bobo,
Rafeeq A Habeeb,
Raymond T Oji,
Rebecca E Dombrowski,
Robert D Tollefsen,
Robert J Ham,
Robert M Barbosa,
Sandra A Boyd,
Susan F Laska, MS,
Susan P Bruederle,
Suyang Qin,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Tina M Pawlowski,
Wayne E Seifert,
William D Tingley,
Yangmin Ning,
Yumi J Hiramine
Montgomery Montgomery, Karen M's Documents
Publish Date | Document Type | Title |
---|---|---|
September, 2022 | EIR | Eli Lilly and Company - EIR, 2023-07-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more